$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

$ormp Overview Financials Valuation SEC Filings Company Website

2012 Q3 Form 10-Q Financial Statement

#000117891312001916 Filed on July 12, 2012

Income Statement

Concept	2012 Q3	2012 Q2	2011 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$400.0K	$290.0K	$300.0K
YoY Change	33.33%	-17.14%	-46.43%
% of Gross Profit
Research & Development	$540.0K	$249.8K	$290.0K
YoY Change	86.21%	3.48%	-50.85%
% of Gross Profit
Depreciation & Amortization	-$10.00K	$10.00K	$10.00K
YoY Change	-200.0%		0.0%
% of Gross Profit
Operating Expenses	$940.0K	$249.8K	$590.0K
YoY Change	59.32%	3.48%	-49.14%
Operating Profit		-$540.4K
YoY Change		-8.63%
Interest Expense	-$1.870M	-$10.00K	$0.00
YoY Change		-100.95%	-100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$2.950M	-$550.4K	-$800.0K
YoY Change	268.75%	-220.33%	-30.43%
Income Tax	$90.00K		-$20.00K
% Of Pretax Income
Net Earnings	-$3.040M	-$550.4K	-$770.0K
YoY Change	294.81%	-220.33%	-34.19%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$508.4K	-$93.70K	-$131.6K
COMMON SHARES
Basic Shares Outstanding	70.45M	70.32M
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q3	2012 Q2	2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.090M	$2.160M	$3.700M
YoY Change	37.57%	-50.23%	184.62%
Cash & Equivalents	$4.431M	$1.300M	$1.513M
Short-Term Investments	$650.0K	$860.0K	$2.190M
Other Short-Term Assets	$36.66K	$40.00K	$20.00K
YoY Change	83.29%	33.33%	0.0%
Inventory
Prepaid Expenses	$2.307K	$21.04K	$1.670K
Receivables	$87.69K	$135.4K	$542.9K
Other Receivables	$84.64K	$127.1K	$24.19K
Total Short-Term Assets	$5.276M	$2.458M	$4.284M
YoY Change	23.16%	-50.13%	206.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.768K	$2.121K	$17.38K
YoY Change	-72.56%	-89.4%	-56.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%	0.0%
Other Assets	$0.00	$0.00	$10.00K
YoY Change	-100.0%
Total Long-Term Assets	$18.38K	$15.79K	$41.86K
YoY Change	-56.1%	-47.37%	-16.29%
TOTAL ASSETS
Total Short-Term Assets	$5.276M	$2.458M	$4.284M
Total Long-Term Assets	$18.38K	$15.79K	$41.86K
Total Assets	$5.295M	$2.474M	$4.326M
YoY Change	22.4%	-50.12%	198.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$600.0K	$310.0K	$380.0K
YoY Change	57.89%	0.0%	-7.32%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$644.4K	$355.9K	$441.3K
YoY Change	46.03%	-1.15%	-4.07%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$870.0K	$150.0K	$160.0K
YoY Change	443.75%	-6.25%	0.0%
Total Long-Term Liabilities	$872.4K	$146.8K	$160.7K
YoY Change	442.79%	-8.23%	0.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$644.4K	$355.9K	$441.3K
Total Long-Term Liabilities	$872.4K	$146.8K	$160.7K
Total Liabilities	$1.517M	$502.7K	$602.0K
YoY Change	151.96%	-3.33%	-2.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$17.89M	-$16.56M	-$14.55M
YoY Change	22.99%
Common Stock	$21.67M	$18.52M	$18.27M
YoY Change	18.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.778M	$1.972M	$3.723M
YoY Change
Total Liabilities & Shareholders Equity	$5.295M	$2.474M	$4.326M
YoY Change	22.4%	-50.12%	198.34%

Cashflow Statement

Concept	2012 Q3	2012 Q2	2011 Q3
OPERATING ACTIVITIES
Net Income	-$3.040M	-$550.4K	-$770.0K
YoY Change	294.81%	-220.33%	-34.19%
Depreciation, Depletion And Amortization	-$10.00K	$10.00K	$10.00K
YoY Change	-200.0%		0.0%
Cash From Operating Activities	-$340.0K	-$880.0K	-$430.0K
YoY Change	-20.93%	51.72%	26.47%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$20.00K	$340.0K	-$10.00K
YoY Change	-300.0%	-3500.0%	-102.5%
Cash From Investing Activities	$20.00K	$340.0K	-$10.00K
YoY Change	-300.0%	-3500.0%	-102.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.490M	0.000	0.000
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-340.0K	-880.0K	-430.0K
Cash From Investing Activities	20.00K	340.0K	-10.00K
Cash From Financing Activities	3.490M	0.000	0.000
Net Change In Cash	3.170M	-540.0K	-440.0K
YoY Change	-820.45%	5300.0%	-833.33%
FREE CASH FLOW
Cash From Operating Activities	-$340.0K	-$880.0K	-$430.0K
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$340.0K	-$880.0K	-$430.0K
YoY Change	-20.93%	51.72%	26.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	dei	Document Period End Date DocumentPeriodEndDate	2012-05-31
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001176309
CY2012Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70453583
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	ORAMED PHARMACEUTICALS INC.
	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	73707	USD
	ormp	Shares Cancelled Value SharesCancelledValue		USD
	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	615882	USD
CY2011	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	26733	USD
	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	19777	USD
CY2011	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3782	USD
	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature		USD
	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature		USD
	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature	108000	USD
	ormp	Imputed Interest Expense ImputedInterestExpense		USD
	ormp	Imputed Interest Expense ImputedInterestExpense	2837	USD
	ormp	Imputed Interest Expense ImputedInterestExpense	23559	USD
	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances		USD
	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances		USD
	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances	6061	USD
	ormp	Receipts On Account Of Shares And Warrants ReceiptsOnAccountOfSharesAndWarrants	6061	USD
	ormp	Stock Issued During Period Value Offering Costs StockIssuedDuringPeriodValueOfferingCosts		USD
	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	91860	USD
	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	821337	USD
CY2011	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	227569	USD
CY2012Q2	ormp	Weighted Average Number Of Basic Shares Used In Computation Of Loss Per Share WeightedAverageNumberOfBasicSharesUsedInComputationOfLossPerShare	70397799
CY2011Q2	ormp	Weighted Average Number Of Basic Shares Used In Computation Of Loss Per Share WeightedAverageNumberOfBasicSharesUsedInComputationOfLossPerShare	69049995
	ormp	Weighted Average Number Of Basic Shares Used In Computation Of Loss Per Share WeightedAverageNumberOfBasicSharesUsedInComputationOfLossPerShare	70199090
	ormp	Weighted Average Number Of Basic Shares Used In Computation Of Loss Per Share WeightedAverageNumberOfBasicSharesUsedInComputationOfLossPerShare	63278472
CY2012Q2	ormp	Weighted Average Number Of Diluted Shares Used In Computation Of Loss Per Share WeightedAverageNumberOfDilutedSharesUsedInComputationOfLossPerShare	70397799
CY2011Q2	ormp	Weighted Average Number Of Diluted Shares Used In Computation Of Loss Per Share WeightedAverageNumberOfDilutedSharesUsedInComputationOfLossPerShare	72410339
	ormp	Weighted Average Number Of Diluted Shares Used In Computation Of Loss Per Share WeightedAverageNumberOfDilutedSharesUsedInComputationOfLossPerShare	70199090
	ormp	Weighted Average Number Of Diluted Shares Used In Computation Of Loss Per Share WeightedAverageNumberOfDilutedSharesUsedInComputationOfLossPerShare	63278472
CY2012Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	308605	USD
CY2011Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	375538	USD
CY2012Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	47252	USD
CY2011Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	47252	USD
CY2012Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	135399	USD
CY2011Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	542891	USD
CY2012Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	15869	USD
CY2011Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		USD
CY2012Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	18446871	USD
CY2011Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	18201111	USD
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	108000	USD
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	18991	USD
CY2012Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70403583
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	80492	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3554921	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	502593	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	108000	USD
CY2012Q2	us-gaap	Assets Assets	2474273	USD
CY2011Q3	us-gaap	Assets Assets	4325937	USD
CY2012Q2	us-gaap	Assets Current AssetsCurrent	2458485	USD
CY2011Q3	us-gaap	Assets Current AssetsCurrent	4284082	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1299865	USD
CY2011Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1920132	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1513365	USD
CY2010Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1199638	USD
CY2002Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-213500	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	720494	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1299865	USD
CY2012Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2011Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2011Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70104583
CY2012Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70403583
CY2011Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70104583
CY2012Q2	us-gaap	Common Stock Value CommonStockValue	70403	USD
CY2011Q3	us-gaap	Common Stock Value CommonStockValue	70104	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16	USD
	us-gaap	Contribution Of Property ContributionOfProperty		USD
	us-gaap	Contribution Of Property ContributionOfProperty		USD
	us-gaap	Contribution Of Property ContributionOfProperty	18991	USD
CY2012Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	500005	USD
CY2011Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	1801400	USD
	us-gaap	Depreciation Depreciation	17384	USD
	us-gaap	Depreciation Depreciation	22840	USD
	us-gaap	Depreciation Depreciation	123491	USD
CY2012Q2	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	1723	USD
CY2011Q3	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent		USD
CY2012Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent		USD
CY2011Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	18502	USD
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.01
CY2011Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.03
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.01
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	6120	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2669	USD
CY2012Q2	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
CY2011Q2	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments	1033004	USD
	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments	1033004	USD
	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments	1033004	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	290668	USD
CY2011Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	350127	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	802273	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	971143	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7760656	USD
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-550365	USD
CY2011Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	457370	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2014259	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-788205	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16411000	USD
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2011Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	150558	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-85435	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-98775	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	308605	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	138054	USD
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	419	USD
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations		USD
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	23094	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	166540	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	47594	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	284482	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-2407	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	7509	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities		USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-8	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	16000	USD
CY2012Q2	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	9164	USD
CY2011Q3	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	10186	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	91860	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	227569	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1139956	USD
CY2012Q2	us-gaap	Liabilities Liabilities	502688	USD
CY2011Q3	us-gaap	Liabilities Liabilities	602021	USD
CY2012Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2474273	USD
CY2011Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4325937	USD
CY2012Q2	us-gaap	Liabilities Current LiabilitiesCurrent	355857	USD
CY2011Q3	us-gaap	Liabilities Current LiabilitiesCurrent	441292	USD
CY2012Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	146831	USD
CY2011Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	160729	USD
CY2012Q2	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	138054	USD
CY2011Q3	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	138054	USD
CY2012Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	357323	USD
CY2011Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	384565	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3694212	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12002997	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1745762	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1690020	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-199905	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1959262	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1283698	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10503227	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-550365	USD
CY2011Q2	us-gaap	Net Income Loss NetIncomeLoss	457370	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2014259	USD
	us-gaap	Net Income Loss NetIncomeLoss	-788205	USD
	us-gaap	Net Income Loss NetIncomeLoss	-16561558	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12986038	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-1561245	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-540420	USD
CY2011Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-591477	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1946688	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1840309	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17191796	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	15869	USD
CY2012Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	10251	USD
CY2011Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	6744	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	39294	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	13532	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	220551	USD
CY2012Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	306	USD
CY2011Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	22587	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	14834	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	32632	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	208866	USD
CY2012Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	127126	USD
CY2011Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	24191	USD
CY2012Q2	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
CY2011Q2	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	434876	USD
CY2012Q2	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
CY2011Q2	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities	43111	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities	240523	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	2109	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities		USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	16402	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2129	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1475	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	125612	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	500000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1690952	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	5928382	USD
CY2012Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	8777	USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments		USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	450000	USD
CY2012Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2121	USD
CY2011Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17376	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	120000	USD
CY2011Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	22675	USD
CY2012Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	21044	USD
CY2011Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1670	USD
CY2012Q2	us-gaap	Prepaid Pension Costs PrepaidPensionCosts	4503	USD
CY2011Q3	us-gaap	Prepaid Pension Costs PrepaidPensionCosts	14293	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	275000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3694212	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	11655693	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	120000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	66243	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	1800000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments		USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	5428000	USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	450000	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	249752	USD
CY2011Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	241350	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1144415	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	869166	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8996264	USD
CY2012Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	16000	USD
CY2011Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	16000	USD
CY2012Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16561558	USD
CY2011Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14547299	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	154199	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	436746	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4854328	USD
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	1971585	USD
CY2011Q3	us-gaap	Stockholders Equity StockholdersEquity	3723916	USD
CY2010Q3	us-gaap	Stockholders Equity StockholdersEquity	830272	USD
CY2002Q2	us-gaap	Stockholders Equity StockholdersEquity	53700	USD
	us-gaap	Stock Issued1 StockIssued1		USD
	us-gaap	Stock Issued1 StockIssued1		USD
	us-gaap	Stock Issued1 StockIssued1	1753	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	275000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7907781	USD
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3694212	USD
	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	434876	USD

Files In Submission

Name	View Source	Status
0001178913-12-001916-index-headers.html	Edgar Link	pending
0001178913-12-001916-index.html	Edgar Link	pending
0001178913-12-001916.txt	Edgar Link	pending
0001178913-12-001916-xbrl.zip	Edgar Link	pending
exhibit_31-1.htm	Edgar Link	pending
exhibit_31-2.htm	Edgar Link	pending
exhibit_32-1.htm	Edgar Link	pending
exhibit_32-2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
ormp-20120531.xml	Edgar Link	completed
ormp-20120531.xsd	Edgar Link	pending
ormp-20120531_cal.xml	Edgar Link	unprocessable
ormp-20120531_def.xml	Edgar Link	unprocessable
ormp-20120531_lab.xml	Edgar Link	unprocessable
ormp-20120531_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zk1211676.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

2012 Q3 Form 10-Q Financial Statement

#000117891312001916 Filed on July 12, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP ORAMED PHARMACEUTICALS INC. Stock $ormp

2012 Q3 Form 10-Q Financial Statement

#000117891312001916 Filed on July 12, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp